Irritable Bowel Syndrome Clinical Trial
Official title:
Effect of Pregabalin on Colonic Motor and Sensory Function in Adults With Irritable Bowel Syndrome With Predominant Constipation
The general aim of the current study is to describe the effect of pregabalin on colonic and
sensory functions in adults with constipation predominant irritable bowel syndrome (IBS-C).
Study hypotheses:
1. Single-dose pregabalin 200mg increases sensation thresholds and decreases sensation
ratings in response to balloon distension in the colon relative to pre-pregabalin
treatment.
2. Single-dose pregabalin 200 mg will increase colonic compliance and decrease colonic
pain and gas thresholds in patients with irritable bowel syndrome constipation
predominant.
3. Single-dose pregabalin 200mg increases the colonic phasic and tonic response to a
standardized meal.
The treatment of patients with irritable bowel syndrome and chronic abdominal pain is
advancing with several effective options for symptoms related to bowel dysfunction and
bloating/distension. However, there are no approved or effective centrally or peripherally
acting visceral analgesics. Pregabalin has been proposed as a treatment for visceral pain,
based on the pharmacological actions, and efficacy in neuropathic pain.
This was a trial in adults with IBS-C to compare the effects of oral pregabalin 200 mg
versus placebo on colon motility, sensation, and tone.
All participants presented on the study day after an overnight bowel preparation with an
oral colonic lavage solution and a 12-hour fast. Flexible colonoscopy to the splenic flexure
was performed without sedation by one investigator. The barostat catheter (constructed at
Mayo Clinic, Rochester, MN) incorporating six manometric point sensors 5 cm apart was
introduced into the colon over a guidewire, and the polyethylene balloon (10 cm long,
cylindrical shape with a maximum volume of 600 ml) was placed in the mid-descending or
junction of the sigmoid and descending colon. A rigid-piston barostat was used to measure
intraballoon pressure and volume throughout the study. After an initial inflation to a
volume of 75 ml to ensure unfolding of the balloon, the operating pressure was identified as
the distension pressure at which respiratory excursions were recorded clearly from the
barostat tracing, and the intraballoon pressure was set 2 mm Hg above the minimal distension
pressure. A conditioning distention from 0 to 20 mmHg in increments of 2 mmHg every 15
seconds was performed over a period of 75 seconds.
After an equilibration period of 10 minutes, a 100-mm visual analog scale (VAS) was used to
assess the level of anxiety or stress experienced by each subject because they are
potentially significant covariates in the assessment of visceral sensation scores.
Colonic compliance was assessed by the ascending methods of limit (ramp-like increases of 4
mm Hg at 60-second intervals). During the assessment of colonic compliance, participants
reported their thresholds for first perception, gas and pain. After another 10 minute
equilibration period, fasting colonic tone was measured at operating pressure for a period
of 10 minutes.
Randomized-order phasic distentions were then applied at 16, 24, 30, and 36 mmHg above the
operating pressure to measure the sensations of gas and pain. Each distention lasted 1
minute and was followed by an equilibration period at the operating pressure for 2 minutes.
A 100-mm visual analog scale (VAS) was used to assess the rating of arousal and stress
experienced by each participant before performing the phasic distentions. During the
distentions, participants also used the 100-mm VAS to rate the intensity of gas and pain
perception at 30 seconds from the start of the distention.
Colonic compliance, fasting tone, pressure thresholds for first perception, gas, and pain,
and VAS scores of gas and pain during the phasic distentions were measured before
administering the study medication and 1 hour after drug administration. After the postdrug
assessment of sensation with phasic distentions, a 30-min assessment of fasting colonic tone
was measured in each participant; this provided a baseline to compare the effect of a
standard 750-ml chocolate milkshake meal across treatment groups. Postprandial tone was
measured over 60 minutes, with the main focus on the first 30 minutes. When the recording
was completed, the balloon was deflated and the tube removed by gentle traction.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |